From the ∗Deming Department of Medicine, Tulane University School of Medicine
†Tulane University School of Medicine
‡Tulane Cancer Center
§Department of Radiology, Tulane University School of Medicine, New Orleans, LA.
Received for publication November 23, 2022; revision accepted February 21, 2023.
Conflicts of interest and sources of funding: O.S. is a consultant to Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc, Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Myovant, Myriad, Noria Therapeutics, Inc, Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, and Theragnostics, and received grant/research support from Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, and Tenebio. The other authors have no conflicts of interest to declare.
Correspondence to: Albert Jang, MD, Deming Department of Medicine, Tulane University School of Medicine, 1430 Tulane Ave #8050, New Orleans, LA 70112. E-mail: [email protected].
